SLN
Silence Therapeutics plc
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
13.27
▲ 0.10 (0.76%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.01
Prev close
13.17
Day high
13.48
Day low
13.13
Volume
734.61K
Market cap
$824.78M
P/E (TTM)
—
52W range
4.19 – 17.58
Day trading desk
Gap from prior close
-1.21%
Prior close 13.17
VWAP
13.28
-0.04% from price
Relative volume
0.78×
Normal
Session range
13.01%
12.83 – 14.50
Position in range
26%
Near session low
ATR (14D)
1.22
9.17% of price
Prior day high
13.57
PDH
Prior day low
13.01
PDL
Bid / ask spread
—
Quote not published
Session volume
735.15K
Avg 948.36K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.28%
-1.9%
1M
+15.90%
+12.2%
3M
+104.47%
+101.4%
6M
+165.40%
+154.3%
YTD
+118.26%
+106.0%
1Y
+148.97%
+129.0%
3Y
+104.15%
+30.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Flagged1
Total notional$101.90K
Call notional$101.90K
Put notional$0
Tiltcall-weighted
Likely opening0 of 1
| Side | Strike | Expiry | Volume | Open int. | Vol / OI | Notional | IV | Score | |
|---|---|---|---|---|---|---|---|---|---|
| CALL | 30.00 | Jan 15, 27 144d |
2.04K | 2.04K | 1.0× | $101.90K | 121% | at bid | 46 |
How this is calculated, and what it cannot see
A contract is flagged when today's volume approaches or exceeds its open interest, the position is worth at least $40,000, and at least 150 contracts changed hands. Open interest is what was outstanding at yesterday's close, so volume above it means the flow cannot all be closing — something is being opened.
The score weights four things: volume against open interest, dollar notional, volume against the rest of that chain, and where the last print sat inside the bid/ask spread.
What it cannot see. Volume here is a daily total, so ten small orders and one large one are indistinguishable — this is not block or sweep detection, which needs exchange-level time and sales. The print column compares the last trade to the current quote, which is a proxy for who was the aggressor, not a tagged flag. Quotes are delayed. A single large trade can be a hedge, a roll, or one leg of a spread, and none of those mean what a naked directional bet would mean.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SLN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.76M
Total on file
Fundamentals
Market cap$824.78M
Enterprise value$555.02M
Revenue (TTM)$615.00K
Gross profit$528.00K
EBITDA$-63.94M
Net income$-59.95M
EPS (TTM)$-1.29
Free cash flow$-23.57M
Total cash$72.05M
Total debt$112.00K
Book value / share$0.81
Shares outstanding62.15M
Float37.84M
Short % of float5.15%
Dividend yield—
Beta (5Y)1.41
Valuation & profitability ratios
Trailing P/E—
Forward P/E-17.35
PEG ratio—
Price / sales—
Price / book16.30
EV / revenue902.47
EV / EBITDA-8.68
Gross margin85.85%
Operating margin-10475.61%
Profit margin0.00%
Return on equity-90.41%
Return on assets-29.65%
Debt / equity0.29
Current ratio7.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $559.00K | $43.26M | $31.64M | $21.66M | -98.7% |
| Operating revenue | $559.00K | $43.26M | $31.64M | $21.66M | -98.7% |
| Cost of revenue | $215.00K | $11.81M | $12.87M | $13.46M | -98.2% |
| Gross profit | $344.00K | $31.45M | $18.78M | $8.19M | -98.9% |
| Research & development | $67.75M | $67.88M | $56.94M | $43.55M | -0.2% |
| Selling, general & admin | $22.34M | $26.88M | $26.22M | $25.68M | -16.9% |
| Total operating expense | $90.10M | $94.77M | $83.16M | $69.23M | -4.9% |
| Operating income | -$89.75M | -$63.32M | -$64.38M | -$61.04M | -41.7% |
| Net interest income | $3.48M | $4.47M | $1.80M | $280.00K | -22.2% |
| Pre-tax income | -$88.60M | -$44.46M | -$53.27M | -$49.65M | -99.3% |
| Tax provision | $11.00K | $845.00K | $956.00K | $688.00K | -98.7% |
| Net income | -$88.61M | -$45.31M | -$54.23M | -$50.33M | -95.6% |
| Net income to common | -$88.61M | -$45.31M | -$54.23M | -$50.33M | -95.6% |
| Basic EPS | -1.89 | -0.99 | -1.47 | -1.56 | -90.9% |
| Diluted EPS | -1.89 | -0.99 | -1.47 | -1.56 | -90.9% |
| EBIT | -$89.75M | -$63.32M | -$64.38M | -$61.04M | -41.7% |
| EBITDA | -$89.20M | -$62.73M | -$63.76M | -$60.44M | -42.2% |
| Basic shares | 47.23M | 46.25M | 37.09M | 32.19M | +2.1% |
| Diluted shares | 47.23M | 46.25M | 37.09M | 32.19M | +2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.28M | $121.33M | $68.79M | $66.34M | -90.7% |
| Cash & short-term investments | $85.11M | $147.33M | $68.79M | $86.10M | -42.2% |
| Accounts receivable | $0 | $972.00K | $290.00K | $1.11M | -100.0% |
| Total current assets | $118.66M | $187.37M | $103.15M | $117.01M | -36.7% |
| Property, plant & equipment | $1.75M | $2.33M | $2.67M | $2.66M | -25.0% |
| Goodwill & intangibles | $10.91M | $9.70M | $10.34M | $10.08M | +12.4% |
| Total assets | $131.44M | $202.63M | $119.45M | $130.10M | -35.1% |
| Total current liabilities | $13.61M | $16.82M | $22.34M | $26.56M | -19.1% |
| Total debt | $160.00K | $117.00K | $346.00K | $539.75K | +36.8% |
| Total liabilities | $69.14M | $68.61M | $97.45M | $103.38M | +0.8% |
| Retained earnings | -$562.57M | -$474.04M | -$431.89M | -$318.60M | -18.7% |
| Shareholder equity | $62.30M | $134.02M | $21.99M | $26.71M | -53.5% |
| Working capital | $105.05M | $170.54M | $80.81M | $90.45M | -38.4% |
| Net tangible assets | $51.40M | $124.32M | $11.65M | $16.63M | -58.7% |
| Shares issued | 141.70M | 141.67M | 118.85M | 107.81M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$88.61M | -$45.31M | -$54.23M | -$50.33M | -95.6% |
| Depreciation & amortisation | $555.00K | $593.00K | $621.00K | $596.00K | -6.4% |
| Stock-based compensation | $8.07M | $16.31M | $16.27M | $12.69M | -50.5% |
| Change in working capital | $10.16M | -$33.02M | -$15.24M | -$19.40M | +130.8% |
| Operating cash flow | -$62.27M | -$67.64M | -$49.46M | -$57.04M | +7.9% |
| Capital expenditure | -$55.00K | -$211.00K | -$56.00K | -$545.00K | +73.9% |
| Investing cash flow | -$47.99M | -$21.97M | $19.29M | -$20.50M | -118.5% |
| Financing cash flow | $15.00K | $142.09M | $31.94M | $52.58M | -100.0% |
| Free cash flow | -$62.33M | -$67.85M | -$49.52M | -$57.59M | +8.1% |
| End cash position | $11.28M | $121.33M | $68.79M | $66.27M | -90.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $422.00K | $34.00K | $159.00K | $224.00K | $142.00K | — | +1,141.2% |
| Operating revenue | $422.00K | $34.00K | $159.00K | $224.00K | $142.00K | — | +1,141.2% |
| Cost of revenue | $11.00K | $12.00K | $64.00K | $85.00K | $54.00K | — | -8.3% |
| Gross profit | $411.00K | $22.00K | $95.00K | $139.00K | $88.00K | — | +1,768.2% |
| Research & development | $9.12M | $8.75M | $20.54M | $17.65M | $20.81M | — | +4.3% |
| Selling, general & admin | $7.03M | $3.73M | $5.79M | $5.13M | $7.68M | — | +88.2% |
| Total operating expense | $16.15M | $12.48M | $26.34M | $22.78M | $28.50M | — | +29.4% |
| Operating income | -$15.74M | -$12.46M | -$26.24M | -$22.64M | -$28.41M | — | -26.3% |
| Net interest income | — | — | — | — | — | $12.43M | — |
| Pre-tax income | -$14.96M | -$11.77M | -$20.96M | -$27.34M | -$28.53M | — | -27.1% |
| Tax provision | $0 | $0 | $1.00K | $10.00K | $0 | — | — |
| Net income | -$14.96M | -$11.77M | -$20.96M | -$27.35M | -$28.53M | — | -27.1% |
| Net income to common | -$14.96M | -$11.77M | -$20.96M | -$27.35M | -$28.53M | — | -27.1% |
| Basic EPS | -0.33 | — | -0.45 | -0.57 | -0.60 | — | — |
| Diluted EPS | -0.33 | — | -0.45 | -0.57 | -0.60 | — | — |
| EBIT | -$15.74M | -$12.46M | -$26.24M | -$22.64M | -$28.41M | — | -26.3% |
| EBITDA | -$15.63M | -$12.35M | -$26.09M | -$22.49M | -$28.27M | — | -26.6% |
| Basic shares | 47.23M | — | 47.23M | 47.23M | 47.23M | — | — |
| Diluted shares | 47.23M | — | 47.23M | 47.23M | 47.23M | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.66M | $11.28M | $82.03M | $41.74M | $64.89M | -49.8% |
| Cash & short-term investments | $70.08M | $85.11M | $102.19M | $114.16M | $136.53M | -17.7% |
| Accounts receivable | $0 | $0 | $28.00K | $85.00K | $41.00K | — |
| Total current assets | $102.85M | $118.66M | $133.63M | $148.55M | $169.79M | -13.3% |
| Property, plant & equipment | $1.54M | $1.75M | $1.85M | $1.83M | $1.80M | -12.0% |
| Goodwill & intangibles | $10.61M | $10.91M | $10.91M | $10.93M | $10.09M | -2.8% |
| Total assets | $115.12M | $131.44M | $146.79M | $165.23M | $185.30M | -12.4% |
| Total current liabilities | $10.46M | $13.61M | $17.38M | $14.77M | $19.26M | -23.2% |
| Total debt | $136.00K | $160.00K | $182.00K | $0 | $60.00K | -15.0% |
| Total liabilities | $65.72M | $69.14M | $72.73M | $71.08M | $298.04M | -4.9% |
| Retained earnings | -$577.53M | -$562.57M | -$550.80M | -$529.84M | $502.54M | -2.7% |
| Shareholder equity | $49.40M | $62.30M | $74.06M | $94.16M | -$112.74M | -20.7% |
| Working capital | $92.39M | $105.05M | $116.25M | $133.78M | $150.53M | -12.0% |
| Net tangible assets | $38.80M | $51.40M | $63.15M | $83.22M | -$122.84M | -24.5% |
| Shares issued | 141.70M | 141.70M | 141.70M | 141.70M | 141.69M | +0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$14.96M | -$11.77M | -$20.96M | -$27.35M | -$28.53M | — | -27.1% |
| Depreciation & amortisation | $106.00K | $113.00K | $156.00K | $148.00K | $138.00K | — | -6.2% |
| Stock-based compensation | $2.45M | -$86.00K | $2.54M | $2.08M | $3.54M | — | +2,945.3% |
| Change in working capital | -$2.65M | -$4.89M | $9.06M | -$4.50M | $10.49M | — | +45.7% |
| Operating cash flow | -$15.60M | -$17.29M | -$10.89M | -$21.78M | -$12.31M | — | +9.7% |
| Capital expenditure | — | — | -$3.00K | -$48.00K | -$4.00K | -$55.77K | — |
| Investing cash flow | $10.00M | -$53.34M | $51.29M | -$1.56M | -$44.38M | — | +118.7% |
| Financing cash flow | $0 | $0 | $0 | $1.00K | $14.00K | — | — |
| Free cash flow | -$15.60M | -$17.29M | -$10.89M | -$21.83M | -$12.31M | — | +9.7% |
| End cash position | $5.66M | $11.28M | $82.03M | $41.74M | $64.89M | — | -49.8% |
Options analytics
Put / call volume
1.11
Put-heavy session
Put / call open interest
0.98
Positioning, not flow
Max pain
15.00
+13.0% from spot
ATM implied vol
143.4%
Nearest strike to spot
Skew (10% OTM)
-3.9%
Calls bid over puts
Call volume
45
Contracts, this expiry
Put volume
50
Contracts, this expiry
Heaviest call OI
15.00
4.07K contracts
Heaviest put OI
12.50
6.48K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.11 | -0.27 | -145.5% |
| Mar 2026 | -0.09 | -0.33 | -266.7% |
| Jun 2025 | -0.18 | -0.57 | -219.3% |
| Sep 2025 | -0.21 | -0.15 | +27.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.16 | 4 | $20.67K | -83.0% |
| Next quarter | -0.17 | 2 | $4.50K | -82.3% |
| Current year | -0.73 | 2 | $324.74K | -22.4% |
| Next year | -0.77 | 2 | $750.53K | +131.1% |
Analyst targets & ownership
Mean target$33.00
High target$75.00
Low target$10.00
Implied upside148.68%
Analyst count6
ConsensusBUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell1 / 0
Held by insiders7.97%
Held by institutions38.33%
Institutions holding90
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.99
-5.16% from price
SMA 20
12.70
+4.50% from price
SMA 50
10.75
+23.40% from price
SMA 100
8.72
+52.09% from price
SMA 200
7.31
+81.55% from price
EMA 12
13.30
-0.22% from price
EMA 26
12.40
+7.02% from price
EMA 50
11.10
+19.54% from price
RSI (14)
56.6
Neutral
MACD (12,26,9)
0.90
Hist -0.08
ATR (14)
1.22
9.17% of price
Realised vol 30D
101.5%
Annualised
Bollinger upper
15.53
20, 2σ
Bollinger lower
9.86
20, 2σ
50 / 200 cross
Golden
10.75 vs 7.31
Trend bias
Above 200
+81.55%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.52
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
101.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-41.9%
Peak to trough
Max drawdown 5Y
-91.7%
Peak to trough
ATR 14
1.22
9.17% of price
Beta (reported)
1.41
5Y monthly, from filing
Short interest
Shares short
1.84M
Prior 1.73M
Change vs prior
+6.0%
Shorts adding
% of float
5.15%
Normal
% of shares out
3.89%
Against total outstanding
Days to cover
3.4
Liquid
Float
37.84M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jun 24, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jun 17, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 16, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 8, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jun 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 13, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| May 9, 25 | Goldman Sachs | MAINTAINED | Sell | Sell |
| May 9, 25 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 9, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 7, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
SEC filings
Offering Registrations
S-3MEF · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K/A · 2026-07-16
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-11
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-22
Offering Registrations
S-3 · 2026-05-18
Headlines
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
MT Newswires · 5d ago
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Business Wire · 9d ago
European Equities Traded in the US Rise in Thursday Trading
MT Newswires · 10d ago
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
Zacks · 10d ago
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Business Wire · 12d ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires · 12d ago
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says
MT Newswires · 12d ago
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
MarketBeat · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.